Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The company is addressing these observations comprehensively
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Subscribe To Our Newsletter & Stay Updated